Pure Global
NCT05458180

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Phase I Cinical Sudy of Lposomal Mitoxantrone Hydrochloride Combined With Cyclophosphamide, Vincristine, Etoposide and Prednisone (CMOEP) in Previously Untreated Peripheral T-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Location
Tianjin, China
Timeline & enrollment
Phase
Phase 1
Start date
Jul 07, 2022
End date
Apr 15, 2025
Enrollment
18 participants
Primary outcome

Maximum tolerated dose (MTD)

Summary

This is a prospective, single arm, multicenter, dose-escalation clinical study to evaluate
 the safety and efficacy of CMOEP in patients with untreated Peripheral T-cell Lymphoma.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05458180
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05458180 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.